Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CD22 | P20273 | 11/20 | 0.38 |
| ▸ | MAG | P20916 | 3/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | CASP1 | P29466 | 1/20 | 0.30 |
| ▸ | CASP3 | P42574 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29326540 | 0.94 | CD22 (0.37) | CD22MAGLMNACASP1CASP3 | |
| SCHEMBL24629760 | 0.91 | CD22 (0.36) | CD22MAGLMNAMEN1KMT2A | |
| SCHEMBL24629735 | 0.91 | CD22 (0.36) | CD22MAGLMNAMEN1KMT2A | |
| SCHEMBL24630057 | 0.90 | CD22 (0.39) | CD22MAGLMNAGAASMN1; SMN2 | |
| SCHEMBL29326548 | 0.89 | CD22 (0.38) | CD22MAGLMNAGAASMN1; SMN2 | |
| SCHEMBL24630238 | 0.88 | CD22 (0.41) | CD22MAGLMNA | |
| SCHEMBL31225657 | 0.87 | CD22 (0.33) | CD22MAG | |
| SCHEMBL24630237 | 0.87 | CD22 (0.34) | CD22MAGLMNA | |
| SCHEMBL24630060 | 0.87 | CD22 (0.34) | CD22MAGLMNA | |
| SCHEMBL24630059 | 0.87 | CD22 (0.42) | CD22MAGLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240238422-A1 | Hypoimmunogenic Biotherapeutics | ADAXION THERAPEUTICS, INC. | 2024-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240238422-A1 | Hypoimmunogenic Biotherapeutics | FCGR3B, CD47, IL2 | CD22 18/4885MAG 321/4885LMNA 4812/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.